Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I

Chikama et al discuss the case of a woman with neurotrophic keratopathy due to trigeminal nerve palsy. She was treated with eye drops containing a substance-P-derived peptide with insulin-like growth factor-I.

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 351; no. 9118; pp. 1783 - 1784
Main Authors:	Chikama, Tai-ichiro, Fukuda, Ken, Morishige, Naoyuki, Nishida, Teruo
Format:	Journal Article
Language:	English
Published:	London Elsevier Ltd 13-06-1998 Lancet Elsevier Limited
Subjects:	Biological and medical sciences Corneal Diseases - drug therapy Corneal Diseases - etiology Cranial Nerve Diseases - complications Drug therapy Drug Therapy, Combination Epithelium, Corneal - drug effects Eye Eyes & eyesight Female Humans Insulin-Like Growth Factor I - therapeutic use Medical disorders Medical sciences Middle Aged Oligopeptides - therapeutic use Paralysis - complications Peptides Pharmacology. Drug treatments Trigeminal Nerve Visual Acuity Wound Healing - drug effects Human Peptides Substance P Keratopathy Insulin like growth factor 1 Case study Neurotrophic factor Eye disease Association Treatment Female Molecular biology Anterior segment disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Chikama et al discuss the case of a woman with neurotrophic keratopathy due to trigeminal nerve palsy. She was treated with eye drops containing a substance-P-derived peptide with insulin-like growth factor-I.
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(98)24024-4